Cargando datos de MNPR: primera visita, tardará unos segundos.
Monopar Therapeutics Inc.
71.20 -0.64 (-0.89%)
- Capitalización de mercado
- $477.9M
- Volumen
- 119K
- Próxima fecha de resultados
- Nov 12, 2026
Monopar Therapeutics Inc. (MNPR): cotización, análisis y datos
Valor intrínseco
Ver planes →Pronóstico del analista
Previsiones bursátiles →$119.00 – $145.00
mediana $130.00 · 82.58% Potencial alcista
Estás viendo el resumen gratuito
Crea una cuenta gratuita para explorar más análisis sobre este valor.
Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$0.62 | +$0.03 | -77.14% |
Métricas
- Precio de compra
- 70.2
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -17.8M
- 1.51
- -2.2
- n/a
- -37.17
- P/B (TTM)
- 3.65
- P/S (TTM)
- n/a
- Fecha de resultados
- Nov 12, 2026
- Precio de venta
- 72.2
- Volumen
- 118,648
- Volumen medio (20D)
- 180,523
- Abierto
- 72.04
- Anterior Cerrar
- 71.84
- Rango del día
- 69.94 - 73.03
- Rango de 52 semanas
- 50.07 - 124.82
- analista
- n/a
- Precio objetivo
- 130 (82.58%)
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Monopar Therapeutics Inc.
Ver perfil →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Industria Biotechnology
Sector Healthcare
IPO Fecha Dec 19, 2019
Empleados 22
Bolsa de Valores NasdaqCM
Símbolo bursátil MNPR
Sitio web https://www.monopartx.com